A four year analysis of variation in use of the anti-neutrophil cytoplasmic antibody (ANCA) test as a screening tool for ANCA-associated systemic vasculitis (AAV) in a teaching hospital.

A four year analysis of variation in use of the anti-neutrophil cytoplasmic antibody (ANCA) test as a screening tool for ANCA-associated systemic vasculitis (AAV) in a teaching hospital.

Bibliographic Details
Main Authors:	McLaren, J, Stimson, R, McRorie, E, Coia, J, Luqmani, R
Format:	Journal article
Published:	2000

Similar Items

Positive predictive value of anti-neutrophil cytoplasmic antibody (ANCA) testing for ANCA-associated systemic vasculitis (AASV) in a routine clinical setting
by: McLaren, J, et al.
Published: (2001)

The diagnostic value of anti-neutrophil cytoplasmic antibody testing in a routine clinical setting.
by: McLaren, J, et al.
Published: (2001)

CONTEXTUALISING QUALITY OF LIFE IN ANCA ASSOCIATED VASCULITIS (AAV)
by: Basu, N, et al.
Published: (2012)

Use of a computerised system to facilitate evaluation of anti-neutrophil cytoplasm (ANCA Associated) vasculitis (AAV) and other forms of systemic vasculitis
by: Luqmani, R, et al.
Published: (2017)

Determinants of Poor Quality of Life in ANCA Associated Vasculitis (AAV).
by: Basu, N, et al.
Published: (2012)

DEVELOPMENT OF DIAGNOSTIC CRITERIA FOR PRIMARY ANCA-ASSOCIATED SYSTEMIC VASCULITIS (AASV)
by: McLaren, J, et al.
Published: (2003)

The UK & Ireland Vasculitis Registry (UKIVAS): Cross-sectional data on the first 2290 Patients with anti-neutrophil cytoplasm (ANCA) associated vasculitis (AAV)
by: Luqmani, R, et al.
Published: (2017)

Relapse in Anti-Neutrophil Cytoplasm Antibody (ANCA)–Associated Vasculitis
by: Alan D. Salama
Published: (2020-01-01)

Cardiovascular disease incidence and risk factors in ANCA-associated primary systemic vasculitis (AASV)
by: Salisbury, E, et al.
Published: (2003)

Comparison of disease activity measures for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis.
by: Merkel, P, et al.
Published: (2009)

Explaining fatigue in ANCA-associated vasculitis
by: Basu, N, et al.
Published: (2013)

Explaining fatigue in ANCA-associated vasculitis.
by: Basu, N, et al.
Published: (2013)

CARDIOVASCULAR AND CEREBROVASCULAR DISEASE INCIDENCE AND RISK FACTORS IN ANCA-ASSOCIATED PRIMARY SYSTEMIC VASCULITIS (AASV)
by: Salisbury, E, et al.
Published: (2004)

INCIDENCE OF NON-FATAL CLINICAL CORONARY EVENTS IN PRIMARY ANCA-ASSOCIATED SYSTEMIC VASCULITIS (AASV)
by: Salisbury, E, et al.
Published: (2003)

DIAGNOSTIC CRITERIA FOR ANCA-ASSOCIATED PRIMARY SYSTEMIC VASCULITIS (AASV) IN PATIENTS PRESENTING WITH ACUTE PULMONARY AND/OR RENAL DISEASE
by: McLaren, J, et al.
Published: (2004)

Diagnosis and assessment of systemic vasculitis.
by: McLaren, J, et al.
Published: (2002)

Pathogenesis and pathology of anti-neutrophil cytoplasmic antibody（ANCA）-associated vasculitis
by: Daisuke Tsukui, et al.
Published: (2021-01-01)

Incidence of non-fatal clinical coronary events in primary ANCA-associated systemic vasculitis (aasv)
by: Salisbury, E, et al.
Published: (2003)

Outcome measures in ANCA-associated vasculitis.
by: Suppiah, R, et al.
Published: (2010)

Damage assessment in ANCA-associated vasculitis.
by: Bhamra, K, et al.
Published: (2012)

The characterisation and determinants of quality of life in ANCA associated vasculitis
by: Basu, N, et al.
Published: (2014)

The characterisation and determinants of quality of life in ANCA associated vasculitis.
by: Basu, N, et al.
Published: (2014)

Validation of the ANCA-associated vasculitis patient-reported outcomes (AAV-PRO) questionnaire
by: Robson, J, et al.
Published: (2018)

Maintenance of clinical remission in ANCA-associated vasculitis.
by: Luqmani, R
Published: (2013)

Hallmark trials in ANCA-associated vasculitis (AAV) for the pediatric rheumatologist
by: Jennifer J. Y. Lee, et al.
Published: (2019-06-01)

The prognostic value of BVAS and VDI in ANCA-AAV
by: Suppiah, R, et al.
Published: (2011)

Cutaneous manifestations of ANCA-associated vasculitis
by: Chiesafuxench, Z, et al.
Published: (2016)

Diagnosis and management of ANCA associated vasculitis.
by: Berden, A, et al.
Published: (2012)

Cardiovascular outcomes in ANCA associated vasculitis
by: Mukhtyar, C, et al.
Published: (2008)

Opinion: Maintenance of clinical remission in ANCA-associated vasculitis
by: Luqmani, R
Published: (2013)

Does a gating policy for ANCA overlook patients with ANCA associated vasculitis? An audit of 263 patients.
by: Arnold, D, et al.
Published: (2010)

CpG oligodeoxynucleotide stimulates production of anti-neutrophil cytoplasmic antibodies in ANCA associated vasculitis
by: Sarvestani Ghafar, et al.
Published: (2008-07-01)

Markers for work disability in ANCA-associated vasculitis
by: Basu, N, et al.
Published: (2013)

Macrophage Migration Inhibitory Factor (MIF) and Thyroid Hormone Alterations in Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (AAV)
by: Mårten Wendt, et al.
Published: (2013-03-01)

Neutrophils in ANCA-associated vasculitis: Mechanisms and implications for management
by: Shangqing Ge, et al.
Published: (2022-09-01)

Predictors of renal involvement in ANCA associated vasculitis
by: Kronbichler, A, et al.
Published: (2018)

ANCA-associated vasculitis: Where can we go from here?
by: Luqmani, R
Published: (2010)

A disease-specific patient-reported outcome for ANCA associated vasculitis: scale structure and measurement properties of the AAV- PRO
by: Robson, J, et al.
Published: (2017)

Personalized Medicine in ANCA-Associated Vasculitis ANCA Specificity as the Guide?
by: Zachary S. Wallace, et al.
Published: (2019-12-01)

Predicting cardiovascular events in patients with newly diagnosed ANCA-AAV
by: Suppiah, R, et al.
Published: (2011)